Proteasome activity and subunit composition in endometrial hyperplasia and cancer
https://doi.org/10.17650/1994-4098-2011-0-4-64-67
Abstract
In endometrial hyperplasia the total proteasome activity was not changed however the 26S proteasome activity was increased in comparison with the normal tissues. In endometrial cancer the high total proteasome activity and activities of 26S and 20S proteasomes wer e revealed. The changes in proteasome activities were correlated with the decreased content of α1α2α3α5α6α7 proteasome subunits and increased con- tents of LMP2, LMP7 and PA28β proteasome subunits compared to that in nonaltered tissues. Low content of α1α2α3α5α6α7 proteasome subunits was revealed at the second stage of cancer patients in comparison with that at the first stage.
About the Authors
L. V. Spirina
Cancer Research Institute, Tomsk Scientific Centre, SB RAMS
Russian Federation
Russian Federation
I. V. Kondakova
Cancer Research Institute, Tomsk Scientific Centre, SB RAMS
Russian Federation
Russian Federation
L. A. Kolomiets
Cancer Research Institute, Tomsk Scientific Centre, SB RAMS
Russian Federation
Russian Federation
A. L. Chernysova
Cancer Research Institute, Tomsk Scientific Centre, SB RAMS
Russian Federation
Russian Federation
O. N. Asadchikova
Cancer Research Institute, Tomsk Scientific Centre, SB RAMS
Russian Federation
Russian Federation
N. P. Sharova
N.K. Koltzov Institute of Developmental Biology RAS, Moscow
Russian Federation
Russian Federation
V. D. Koval
Cancer Research Institute, Tomsk Scientific Centre, SB RAMS
Russian Federation
Russian Federation
References
1. Чепик О.Ф. Морфогенез гиперпластических процессов эндометрия. Практ онкол 2004;5(1):9–15.
2. Lacey J.V.Jr., Sherman M.E., Ronnet B.M. et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28(5):788–92.
3. Спирина Л.В., Кондакова И.В. Роль внутриклеточного специфического протеолиза в онкогенезе. Вопр онкол 2008; (6):690–4.
4. Sharova N., Zakharova L. Multiple forms of proteasomes and their role in tumor fate. Recent patents on endocrine. Metabol Immun Drug Discov 2008;2(3):152–61.
5. Ротанова Т.В., Мельников Э.Э. АТР-зависимые протеиназы и протеолитические комплексы внутриклеточной деградации белков. Биомед химия 2008;54(5):512–30.
6. Emmerich N.P.N., Nussbaum A.K., Stevanovic S. et al. The human 26S and 20S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J Biol Chem 2000;275:21140–8.
7. Almond J.B., Cohen G.M. The proteasome; a novel target for cancer chemotherapy. Leukemia 2002;16:433–43.
8. Fuchs D., Berges C., Opelz G. et al. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008;103(1):270–83.
9. Спирина Л.В., Кондакова И.В., Чойнзонов Е.Л. и др. Активность протеасом в тканях злокачественных опухолей различных локализаций. Сиб онкол журн 2009;(5):49–52.
10. Dolcet X., Llobet D., Encinas M. et al. Proteasome inhibitors induce death but activate NF-B on endometrial carcinoma cell lines and primary culture explants. J Biol Chemistry 2006;281:22118–30.
11. Абрамова Е.Б., Астахова Т.М., Ерохов П.А., Шарова Н.П. Множественность форм протеасомы и некоторые подходы к их разделению. Изв РАН Сер биол 2006;(2):150–6.
12. Ben-Shahar S., Komlosh A., Nadav E. et al. 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J Biol Chem 1999;274(31):21963–72.
13. Ghersi G. Roles of molecules involved in epithelial/mesenchymal transition during angiogenesis. Front Biosci 2008;1(13):2335–55.
14. Heaphy C.M., Griffith J.K., Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Res Treat 2009;118(2):229–39.
15. Arlt A., Bauer I., Schafmayer C. et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation
16. of nuclear factor E2-related factor 2 (Nrf2). Oncogene 2009;28:3983–96.
Review
For citations:
Spirina L.V., Kondakova I.V., Kolomiets L.A., Chernysova A.L., Asadchikova O.N., Sharova N.P., Koval V.D. Proteasome activity and subunit composition in endometrial hyperplasia and cancer. Tumors of female reproductive system. 2011;(4):64-67. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-4-64-67
Views:
551
Email this article 